| abstract |
The present invention relates to novel compounds, in particular the novel pyridinone derivatives according to formula (I) wherein all radicals are defined in the specification and claims. The compounds according to the present invention are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases associated with the mGluR2 subtype of metabotropic receptors, as positive allosteric modulators of metabotropic receptor-subtype 2 ("mGluR2 & useful. In particular, the diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The present invention also relates to pharmaceutical compositions and methods of making the compounds and compositions, and their use for the prophylaxis or treatment of diseases in which mGluR2 is involved. |